The Global Market for Human Growth Hormone (hGH) Drugs is Forecast to Reach US$4.5 Billion by 2022

Growing Commitment towards Improving Early Diagnosis for Rare Diseases to Benefit the Market for Human Growth Hormone Drugs, According to New Report by Global Industry Analysts, Inc.

                                                                                                

GIA launches comprehensive analysis of industry segments, trends, growth drivers, market share, size and demand forecasts on the global Human Growth Hormone Drugs market. The global market for Human Growth Hormone (hGH) Drugs is forecast to reach US$4.5 billion by 2022, driven by the growing commitment of the medical community to develop innovative diagnostics that support early diagnosis and intervention of devastating rare diseases and disorders and increased demand for effective therapies.   

The market for recombinant growth hormone is growing, driven by the high unmet medical needs in the treatment of growth hormone disorders. Low differentiation among available products, patent expiries and entry of generics have fuelled competition and pricing pressures thereby substantially eroding prices in the market. Factors such as improving diagnosis rate and the resulting increase in treated patient volumes are spurring growth in the market. Off label promotion of hGH drugs as anti-aging therapies is expected to benefit from the rapidly aging population although amid controversies.  Opportunities for growth exist in emerging markets, such as Asia-Pacific, where the market remains highly underpenetrated.

Pediatric growth hormone deficiency represents the largest market for recombinant growth hormones worldwide. Pertinently, a sizable chunk of new products in development target this patient population that has historically remained the largest consumers for hGH products. Non-pediatric GHD also remains an important market, primarily in the West with sizable share accounted for by adult GHD patients. As per some estimates, around half of adult GHD patients do not receive any treatment for their growth deficiencies. The global somatropin market is dominated by daily-dose Sustained-Release hGH drugs (SRhGH), such as Genotropin, Humatrope, Norditropin, Nutropin/Nutropin AQ, Omnitrope, Saizen, and Tev-Tropin that are developed and marketed by a handful of major pharma companies. Continuous development of next generation hGH products is critical for manufacturers of originator drugs, given the emergence of biosimilars and impending patent expiries. The biosimilar market is nascent and adoption is largely limited to new patients, since healthcare providers often refrain from switching drug regimens for existing patients already on treatment. The launch of biobetters or follow-on branded biologic drugs has played a critical role in restricting the penetration of biosimilars.

As stated by the new market research report on Human Growth Hormone Drugs, the United States represents the largest market worldwide. Asia-Pacific ranks as the fastest growing market with a CAGR of 5.8% over the analysis period, fuelled by macro factors such as population growth, increased healthcare spending, favorable regulatory scenario, developing healthcare infrastructure and increasing accessibility and affordability of hGH drugs and therapies.

Major players covered in the report include Eli Lilly and Company, Ferring Holding SA, Genentech Inc., GeneScience Pharmaceuticals Co. Ltd., Merck KgaA, Novo Nordisk A/S, Pfizer Inc., and Sandoz International GmbH, among others.

The research report titled “Human Growth Hormone Drugs: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of growth drivers, inhibitors, market trends, drugs in pipeline, competitive and regulatory scenario, recent drug approvals, mergers, acquisitions, and other strategic industry activities of major companies worldwide. The report provides market estimates and projections for major geographic markets including the United States, Canada, Japan, Europe (France, Germany, Italy, UK, Spain, and Rest of Europe), Asia-Pacific, and Rest of World. The global hGH drugs market is further analyzed by sales revenues of drug brands such as Norditropin, Genotropin, Humatrope, Nutropin, Saizan, and Others.

Global Industry Analysts, Inc. 6150 Hellyer Ave., San Jose CA 95138, USA, All Rights Reserved.